YN
Therapeutic Areas
Emmaus Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Endari (L-glutamine oral powder) | Sickle Cell Disease | Approved |
| L-glutamine | Diverticulosis | Research |
| Cell Sheet Engineering | Not Specified (Regenerative Medicine) | Research |
| IRAK4 Inhibitor | Oncology | Preclinical |